The CopCov Study

The CopCov Study Randomised double-blind, placebo-controlled trial

COPCOV is the largest pre-exposure prophylaxis Randomised Controlled Trial.

“Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV).

We are pleased to announce that RSUP Dr. Sardjito is the latest site to recruit into the world’s largest prophylaxis stu...
17/11/2021

We are pleased to announce that RSUP Dr. Sardjito is the latest site to recruit into the world’s largest prophylaxis study (nearly 4000 recruits), which still aims to answer the important question- do Chloroquine and Hydroxychloroquine prevent COVID-19.

The results of this study can still be beneficial to those who are not vaccinated around the world, if immunity wanes and if new variants come into circulation with decreased vaccine efficacy.

For more information on this research, please contact utsamani.cintyamena@mail.ugm.ac.id

Patient-centred research is the core of our research activities, spanning 5 research units and over 50 research sites in Asia and Africa.

20/09/2021

Today the COPCOV study has reached the important milestone of 3,000 participants enrolled!!! A fantastic contribution to recruitment from many sites and participants around the world (Benin, Côte d’Ivoire, Indonesia (Surabaya and Medan), Kenya (Mbagathi and Eldoret), Mali, Nepal, Niger, Pakistan, Thailand, the U.K. and Zambia).

07/09/2021

Congratulations to the fantastic team at the Fountain Health Care Hospital, Eldoret, Kenya!! The latest site to be recruiting into the COPCOV study. Next milestone- 3,000 participants.

01/09/2021

B.P. Koirala Institute of Health Sciences (BPKIHS), Dharan, Nepal has recruited more than 200 participants into the COPCOV study over the last month!! A great testament to the team’s hard work and perseverance in the face of sizeable challenges.

01/09/2021

The COPCOV study is open and recruiting in Niamey, Niger. The study is currently active in 12 other African sites in 6 countries and with >2,400 participants at last count, aims to help answer the question as to the role of HCQ in prevention of COVID-19.

06/08/2021

Bunda Tharmin Hospital & Teguh Memorial Hospital (Medan, Indonesia) have begun recruitment and the study total is now >1,700 participants. Amazing effort from all those involved but still much to be done!

ที่อยู่

Dusit

แจ้งเตือน

รับทราบข่าวสารและโปรโมชั่นของ The CopCov Studyผ่านทางอีเมล์ของคุณ เราจะเก็บข้อมูลของคุณเป็นความลับ คุณสามารถกดยกเลิกการติดตามได้ตลอดเวลา

ติดต่อ การปฏิบัติ

ส่งข้อความของคุณถึง The CopCov Study:

แชร์

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram